Previous close | 0.2500 |
Open | 0.2500 |
Bid | 0.0000 |
Ask | 4.2000 |
Strike | 165.00 |
Expiry date | 2024-06-21 |
Day's range | 0.2500 - 0.2500 |
Contract range | N/A |
Volume | |
Open interest | 64 |
Biogen (BIIB) and Eisai start the rolling submission of a biologics license application to the FDA for Leqembi subcutaneous autoinjector as a weekly maintenance dosing regimen for early Alzheimer's disease.
Eli Lilly stock broke out and then retreated into sell-zone territory. With shares on the rise again, is LLY stock a buy?
Biogen stock jumped early Wednesday after the FDA gave its Eisai-partnered Alzheimer's treatment a fast track designation.